Quantcast
Last updated on April 23, 2014 at 12:06 EDT

Latest AngioDynamics Inc. Stories

2013-04-02 16:26:20

Gift supports SIRF's Discovery Campaign to expand minimally invasive medicine FAIRFAX, Va., April 2, 2013 /PRNewswire-USNewswire/ -- The Society of Interventional Radiology Foundation's Discovery campaign will benefit from a $500,000 pledge by new "Futurist" level supporter, medical device manufacturer AngioDynamics. "Initiatives of this kind continue to reinforce opportunities for investment in the specialty's future, with funding that supports grants, research consensus panels,...

2012-09-11 10:24:46

NEW YORK, Sept. 11, 2012 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating AngioDynamics (NASDAQ: ANGO), and its Board of Directors in connection with the compensation provided to certain of its executive officers. (Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO) To get more information, click here: http://zlk.9nl.com/ango. There is no cost or obligation to you. If you own common stock in AngioDynamics and wish to obtain additional information, please contact Eduard...

2008-11-06 06:00:21

AngioDynamics Inc. (NASDAQ:ANGO) today announced it will launch a new varicose vein therapy brand, VenaCure EVLT, at the American College of Phlebology (ACP) 22nd Annual Congress, November 6th to 9th at the Marco Island Marriott Resort & Spa in Florida. The new brand will encompass the best of AngioDynamics' VenaCure(R) product line as well as EVLT(R), a product line which AngioDynamics recently rescued from the bankruptcy of Diomed Inc. Participants at the ACP Congress will find the...

2008-10-24 06:00:24

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that at its annual meeting shareholders elected Charles Orsatti to the Board of Directors. Mr. Orsatti succeeds Robert Flaherty who decided to not pursue re-election to the Board. The size of the AngioDynamics Board of Directors remains unchanged, at nine members....

2008-10-15 09:00:47

Delcath Systems, Inc. (NASDAQ: DCTH) today announced the appointment of Mr. Eamonn Hobbs to Delcath's Board of Directors. Mr. Hobbs is President and Chief Executive Officer of AngioDynamics, Inc. (NASDAQ: ANGO), a leading medical device company specializing in the development and sales of medical technology serving the needs of interventional oncologists and vascular interventionalists. Mr. Hobbs, a Co-Founder of AngioDynamics, built his company into a leading medical technology company...

2008-10-02 18:00:30

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, today reported financial results for the first quarter ended August 31, 2008. Financial results include the acquisition of Diomed assets since June 17, 2008, the date of acquisition. Net sales in the fiscal first quarter were $44.3 million, an 18% increase over the $37.5...

2008-07-23 06:00:57

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that it has appointed Agustin Gago, 49, as the Company's Vice President of International IRE Sales, a newly created position at the Company. Mr. Gago will report to Eamonn Hobbs, President and CEO of AngioDynamics, and will be responsible for developing...

2008-07-14 06:00:12

AngioDynamics (NASDAQ:ANGO) announced today results from its RAPTURE study, which was conducted to identify the feasibility, efficacy and safety of percutaneous radiofrequency ablation (RFA) of malignant lung tumors. Published in The Lancet Oncology July 2008 issue, the results show a high proportion of sustained, complete tumor response after treatment with RFA. This prospective, intention-to-treat clinical trial enrolled 106 patients with 183 lung tumors that were 3.5 cm in diameter or...

2008-07-10 18:00:46

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that it has initiated a voluntary recall of all hospital inventory of Centros(TM), its self-centering central venous catheter for dialysis. The Company became aware that the catheter cuff, a component intended to anchor the catheter in...

2008-06-18 18:00:45

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that it has completed its acquisition of certain U.S. and U.K assets of Diomed, Inc. The purchase price for the assets is $11 million subject to adjustment for changes in working capital to be determined subsequent to the closing date. "With the...